4.94
price up icon1.23%   0.06
after-market After Hours: 4.82 -0.12 -2.43%
loading
Bio Green Med Solution Inc stock is traded at $4.94, with a volume of 15,016. It is up +1.23% in the last 24 hours and up +0.00% over the past month. Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
See More
Previous Close:
$4.88
Open:
$4.75
24h Volume:
15,016
Relative Volume:
1.71
Market Cap:
$11.06M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
Value
$4.75
$5.00
1-Week Range:
Value
$4.59
$5.15
52-Week Range:
Value
$4.0408
$5.75

Bio Green Med Solution Inc Stock (BGMS) Company Profile

Name
Name
Bio Green Med Solution Inc
Name
Phone
908-517-7330
Name
Address
200 CONNELL DRIVE, BERKELEY HEIGHTS
Name
Employee
12
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
BGMS's Discussions on Twitter

Compare BGMS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
BGMS
Bio Green Med Solution Inc
4.94 14.34M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
391.64 101.35B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
456.00 58.66B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
562.27 59.43B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
737.56 44.01B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
340.70 36.56B 3.81B -644.79M -669.77M -6.24

Bio Green Med Solution Inc Stock (BGMS) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-18-22 Resumed Oppenheimer Outperform
Apr-27-20 Resumed ROTH Capital Buy
Sep-07-18 Initiated Ladenburg Thalmann Buy
Oct-16-15 Initiated H.C. Wainwright Buy
Feb-04-10 Initiated Roth Capital Buy
Oct-28-09 Initiated Merriman Buy
Aug-12-08 Initiated Piper Jaffray Buy
Mar-12-08 Reiterated Cantor Fitzgerald Buy
Mar-12-08 Reiterated Collins Stewart Buy
Mar-12-08 Reiterated Needham & Co Buy
Nov-27-07 Reiterated Cantor Fitzgerald Buy
Aug-10-07 Reiterated Cantor Fitzgerald Buy
Jun-04-07 Reiterated Needham & Co Buy
Apr-23-07 Initiated Lazard Capital Buy
Apr-10-07 Initiated Cantor Fitzgerald Buy
View All

Bio Green Med Solution Inc Stock (BGMS) Latest News

pulisher
Sep 26, 2025

Biodexa Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:BDRX - Benzinga

Sep 26, 2025
pulisher
Sep 25, 2025

Bio Green Med Solution Appoints New Independent Director - TipRanks

Sep 25, 2025
pulisher
Sep 16, 2025

Cyclacel Pharmaceuticals: Recent Acquisition Completed - MSN

Sep 16, 2025
pulisher
Sep 16, 2025

Bio Green Med Solution Faces Nasdaq Delisting Notice - TipRanks

Sep 16, 2025
pulisher
Sep 12, 2025

BlackRock® Canada Announces Product Changes - The Manila Times

Sep 12, 2025
pulisher
Sep 12, 2025

Inception Growth Acquisition Limited Announces Additional Contribution to Trust Account to Extend Business Combination Period - The Manila Times

Sep 12, 2025
pulisher
Sep 12, 2025

Bio Green Med Solution announces closing of strategic acquisition of Fitters Sdn. Bhd. - MarketScreener

Sep 12, 2025
pulisher
Sep 12, 2025

Bio Green Med Solution, Inc. Completes Acquisition of Fitters Sdn. Bhd. to Diversify Business Portfolio - Quiver Quantitative

Sep 12, 2025
pulisher
Sep 10, 2025

Major Shareholder Cashes Out Big on Cyclacel Pharmaceuticals! - TipRanks

Sep 10, 2025
pulisher
Sep 05, 2025

Cyclacel Pharmaceuticals Approves Key Shareholder Proposals - TipRanks

Sep 05, 2025
pulisher
Sep 05, 2025

Cyclacel Pharmaceuticals shareholders approve share issuance and name change - Investing.com

Sep 05, 2025
pulisher
Sep 02, 2025

Cyclacel Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3) - MarketScreener

Sep 02, 2025
pulisher
Jul 16, 2025

Big Moves And Bigger Questions For Biotech And Tech Stocks - Finimize

Jul 16, 2025
pulisher
Jul 02, 2025

Cyclacel Pharmaceuticals to Implement 1-for-15 Reverse Stock Split; Shares Fall - MarketScreener

Jul 02, 2025
pulisher
Jun 19, 2025

Cyclacel Pharmaceuticals, Inc. announced that it has received $3 million in funding - MarketScreener

Jun 19, 2025
pulisher
Jun 03, 2025

CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT - MarketScreener

Jun 03, 2025
pulisher
May 06, 2025

Fitters swaps fire safety arm for 19.99% stake in Nasdaq biotech firm - The Malaysian Reserve

May 06, 2025
pulisher
Apr 28, 2025

Wacker Buys Manufacturing Assets and Know-how of Bio Med Sciences - CHEManager

Apr 28, 2025
pulisher
Feb 27, 2025

Cyclacel Pharmaceuticals, Inc. Announces Chief Executive Officer Changes - MarketScreener

Feb 27, 2025
pulisher
Oct 25, 2024

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule - MarketScreener

Oct 25, 2024
pulisher
Oct 23, 2024

Roth MKM Downgrades Cyclacel Pharmaceuticals(CYCC.US) to Hold Rating - 富途牛牛

Oct 23, 2024
pulisher
Sep 04, 2024

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter - MarketScreener

Sep 04, 2024
pulisher
May 31, 2024

WACKER Positions itself as Solution Provider for Silicone-Coated Healthcare Products with New Acquisition - PR Newswire

May 31, 2024
pulisher
May 09, 2024

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results - MarketScreener

May 09, 2024
pulisher
Feb 21, 2024

Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO and Investor Conference - MarketScreener

Feb 21, 2024
pulisher
Jan 31, 2024

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer - MarketScreener

Jan 31, 2024
pulisher
Aug 10, 2023

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - MarketScreener

Aug 10, 2023
pulisher
May 12, 2023

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update - MarketScreener

May 12, 2023
pulisher
May 04, 2023

Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit - MarketScreener

May 04, 2023
pulisher
Jan 29, 2022

Alaunos Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:TCRT - Benzinga

Jan 29, 2022
pulisher
Apr 07, 2021

Waste biorefinery towards a sustainable circular bioeconomy: a solution to global issues - Biotechnology for Biofuels and Bioproducts

Apr 07, 2021
pulisher
Feb 24, 2021

Cyclacel Pharmaceuticals Announces Management Changes - MarketScreener

Feb 24, 2021
pulisher
Jan 21, 2021

Psyence Biomedical Stock Price, Quotes and Forecasts | NASDAQ:PBM - Benzinga

Jan 21, 2021
pulisher
Dec 22, 2020

Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures - MarketScreener

Dec 22, 2020
pulisher
Jan 24, 2018

Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference - MarketScreener

Jan 24, 2018

Bio Green Med Solution Inc Stock (BGMS) Financials Data

There is no financial data for Bio Green Med Solution Inc (BGMS). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.66
price down icon 2.36%
$84.81
price up icon 1.10%
$30.67
price up icon 4.57%
$98.62
price up icon 0.53%
$144.01
price up icon 1.67%
biotechnology ONC
$340.70
price up icon 2.36%
Cap:     |  Volume (24h):